We can’t show the full text here under this license. Use the link below to read it at the source.
Dihydromyricetin Alleviates Non-Alcoholic Fatty Liver Disease by Modulating Gut Microbiota and Inflammatory Signaling Pathways
Dihydromyricetin may improve fatty liver disease by changing gut bacteria and inflammation signals
AI simplified
Abstract
Dihydromyricetin (DHM) treatment significantly reduced serum levels of LPS, IL-1β, and TNF-α in mice with non-alcoholic fatty liver disease (NAFLD).
- NAFLD was induced in mice using a high-fat diet over 8 weeks.
- DHM treatment decreased liver expression of TLR4 and NF-κB p65.
- Intestinal flora analysis revealed an increase in beneficial bacteria, particularly in medium and high-dose groups.
- DHM treatment improved liver pathology by reducing fat deposition and inflammatory cell infiltration.
- Results suggest that DHM may prevent NAFLD progression by balancing gut microbiota and inhibiting inflammation.
AI simplified